Marianne Alexandersson - Enzymatica Publ Independent Director
| ENZY Stock | SEK 1.75 0.02 1.13% |
Director
Ms. Marianne Dicander Alexandersson has served as Independent Member of the Board of Directors of Enzymatica AB since May 19, 2014. She is Chief Executive Officer and Chairman of the Board of MDA Management AB. Previously, she was Chief Executive Officer of Global Health Partners AB, Sjatte APfonden and Kronans Droghandel, as well as Deputy Chief Executive Officer at Apoteket AB. She is also Member of the Board of Camurus AB and Recipharm AB, Chairman of the Board of Sahlgrenska Science Park, Member of Skandia, as well as Chairman of The Royal Swedish Academy of Engineering Sciences. She holds a MS degree in Chemical Engineering. since 2014.
| Age | 60 |
| Tenure | 10 years |
| Phone | 46 4 62 86 31 00 |
| Web | https://www.enzymatica.se |
Enzymatica Publ Management Efficiency
The company has return on total asset (ROA) of (0.1909) % which means that it has lost $0.1909 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4032) %, meaning that it generated substantial loss on money invested by shareholders. Enzymatica Publ's management efficiency ratios could be used to measure how well Enzymatica Publ manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | DIRECTOR Age | ||
| Anders MartinLof | Cantargia AB | 48 | |
| Karin Leandersson | Cantargia AB | 43 | |
| Claus Andersson | Cantargia AB | 51 | |
| Patricia Delaite | Cantargia AB | 53 | |
| Thoas Fioretos | Cantargia AB | 53 | |
Management Performance
| Return On Equity | -0.4 | |||
| Return On Asset | -0.19 |
Enzymatica publ AB Leadership Team
Elected by the shareholders, the Enzymatica Publ's board of directors comprises two types of representatives: Enzymatica Publ inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enzymatica. The board's role is to monitor Enzymatica Publ's management team and ensure that shareholders' interests are well served. Enzymatica Publ's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enzymatica Publ's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bengt Baron, Independent Chairman of the Board | ||
| Mats Clarsund, Executive Vice President for Research and Development | ||
| Stefan Olsson, Communication Mang | ||
| Claus Egstrand, Chief Commercial Officer | ||
| Ulf Blom, Executive Vice President Marketing and Operations | ||
| Louise Nicolin, Director | ||
| Anna Isaksson, Vice President Quality and Regulatory Management | ||
| Therese Filmersson, Chief Financial Officer | ||
| Marianne Alexandersson, Independent Director | ||
| Gudmundur Palmason, Director | ||
| Jorgen Rexo, Executive Vice President Legal, Director | ||
| Mats Andersson, Director | ||
| Fredrik Lindberg, Chief Executive Officer | ||
| Johan Lindvall, Chief Operating Officer, Executive Vice President |
Enzymatica Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enzymatica Publ a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (1.12) % | |||
| Operating Margin | (1.12) % | |||
| Current Valuation | 613.36 M | |||
| Shares Outstanding | 164.26 M | |||
| Shares Owned By Insiders | 64.15 % | |||
| Shares Owned By Institutions | 1.71 % | |||
| Price To Earning | (6.00) X | |||
| Price To Book | 47.25 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Enzymatica Stock Analysis
When running Enzymatica Publ's price analysis, check to measure Enzymatica Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzymatica Publ is operating at the current time. Most of Enzymatica Publ's value examination focuses on studying past and present price action to predict the probability of Enzymatica Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzymatica Publ's price. Additionally, you may evaluate how the addition of Enzymatica Publ to your portfolios can decrease your overall portfolio volatility.